In Brief: A New Formulation of Posaconazole (Noxafil) .................................................. p 20

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints or call customer service at: 800-211-2769
IN BRIEF

A New Formulation of Posaconazole (Noxfil)

The FDA has approved an IV formulation of the antifungal drug posaconazole (Noxfil - Merck) for prophylaxis of Aspergillus and Candida infections in adults at high risk for these infections, such as those with prolonged neutropenia. Posaconazole is also available as delayed-release tablets and an oral suspension.

With activity against Aspergillus and Candida, posaconazole has an antifungal spectrum similar to that of voriconazole (Vfend, and generics), but unlike voriconazole it is also active against many species of Mucorales (formerly called Zygomycetes), such as *Mucor* and *Rhizopus*. Posaconazole has variable activity against *Fusarium* spp. and *Scedosporium* spp.¹

Fever, diarrhea, nausea, vomiting, rash, headache, fatigue, hypokalemia, QT interval prolongation, and abnormal liver function have been reported with posaconazole. Anhypoalbuminemia, toxic epidermal necrolysis, angioedema, and anaphylaxis have occurred rarely.

Posaconazole is primarily metabolized via UDP glucuronidation; it is also a substrate of P-glycoprotein (P-gp). Drugs that inhibit or induce these clearance pathways may alter serum concentrations of posaconazole. Posaconazole is a strong inhibitor of CYP3A4 and may increase serum concentrations of drugs that are primarily metabolized by this pathway.² Taking posaconazole with other drugs that prolong the QT interval (www.crediblemeds.org), especially those metabolized by CYP3A4, may increase the risk of QT interval prolongation.

The new formulation of posaconazole is available in 300 mg/16.7 mL vials. The recommended dosage is 300 mg administered intravenously over 90 minutes twice on day 1 and once daily thereafter. To avoid accumulation of the vehicle, patients with moderate or severe renal impairment should not receive IV posaconazole. One vial of Noxfil costs $530.50.³

3. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. January 5, 2015. Reprinted with permission by First Databank, Inc. All rights reserved. ©2015. www.fdbhealth.com/policies/drug-pricing-policy.

---


CONTRIBUTING EDITORS: Carl W. Bazl, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; Jane P. Gagliardi, M.D., M.H.S., F.A.C.P., Duke University School of Medicine; Jules Hirsch, M.D., Rockefeller University; David N. Jurelink, BPhm., M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Hans Meinertz, M.D., University Hospital, Copenhagen; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schafer, M.D., M.P.H., Harvard Medical School, F. Estelle R. Simons, M.D., University of Manitoba, Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR: Susie Wong; ASSISTANT MANAGING EDITOR: Liz Donohue; EDITORIAL ASSISTANT: Cheryl Brown

EXECUTIVE DIRECTOR OF SALES: Gene Carbona; Fulfillment & SYSTEMS MANAGER: Cristine Romatowski; DIRECTOR OF MARKETING COMMUNICATIONS: Joanne F. Valentino; VICE PRESIDENT AND PUBLISHER: Yosef Wolnisher-Levy

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. is supported solely by subscription fees and accepts no advertising, grants, or donations. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Permissions: To reproduce any portion of this issue, please e-mail your request to permissions@medicalletter.org

Subscriptions (US): 1 year - $38; 2 years - $76; 3 years - $119; 4 years - $164. Special rates available for bulk subscriptions.

Site License Inquiries: E-mail: info@medicalletter.org


Customer Service: Call: 800-211-2769 or 914-235-0500 Fax: 914-632-1733 E-mail: custserv@medicalletter.org

Copyright 2015. ISSN 1523-2859

Published by The Medical Letter, Inc. • A Nonprofit Organization